Helsinn Healthcare enters strategic alliance with IS Pharma, including selling Irish unit

2 February 2011

Swiss pharma group Helsinn Healthcare has entered into a strategic alliance with UK-based IS Pharma to develop their businesses in the field of cancer and supportive care. The alliance will contribute in three areas:

• A collaboration and option agreement over products in cancer and supportive care.
• Licensing of rights to IS Pharma for the UK and Ireland of NETU-PALO FDC (fixed dose combination of netupitant and palonosetron), a next generation treatment in development for the prevention of nausea and vomiting associated with cancer chemotherapy.
• Acquisition by IS Pharma of Helsinn’s Irish commercial operations, Helsinn Birex Therapeutics (HBT).

Collaboration and option agreement

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK